Top Markets
#1 Akedo Akedo +136.52%
#2 TENDIES TENDIES +87.88%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +43.74%
#5 Bitway Bitway +27.02%
#6 Mubarak Mubarak +25.52%
#7 Cash Cat Cash Cat +23.53%
#8 Palladium Network Palladium Network +22.71%
#9 MultiversX MultiversX +20.20%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Peringkat dalam Saham #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Harga Saham
$8.16
Terakhir disinkronkan: 2025-06-26
Kapitalisasi Pasar
$234.57M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Regulus Therapeutics Inc. (RGLS)

Kategori

Healthcare
Laba untuk Regulus Therapeutics Inc. (RGLS)
Laba pada Mar 2025 TTM: $-47.52M
Menurut laporan keuangan terbaru dari Regulus Therapeutics Inc., laba saat ini perusahaan adalah $-47.52M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-30.04M, penurunan dibandingkan dengan laba tahun 2022 sebesar $-28.32M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Regulus Therapeutics Inc. dari 2010 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
2026 (TTM) $-47.52M 2.51%
2024 $-46.36M 54.34%
2023 $-30.04M 6.05%
2022 $-28.32M 1.85%
2021 $-27.81M 76.78%
2020 $-15.73M -15.39%
2019 $-18.59M -61.78%
2018 $-48.65M -32.53%
2017 $-72.10M -11.90%
2016 $-81.84M 46.76%
2015 $-55.77M -1.61%
2014 $-56.68M 203.24%
2013 $-18.69M 7.31%
2012 $-17.42M 135.51%
2011 $-7.40M -52.56%
2010 $-15.59M 0.00%
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -11,199.91%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -4,204.73%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 6,395.94%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 8,351.24%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH